Get this delivered to your inbox, and more info about our products and services. Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Ben is the Retirement and Investing Editor for Forbes Advisor. With two decades of business and finance journalism experience, Ben has covered breaking market news, written on equity markets for Investopedia, and edited personal finance content for Bankrate and LendingTree.

Northrop Grumman led the cohort of defense stocks, soaring as much as 12% on Monday. Meanwhile,  General Dynamics jumped 9%, Lockheed Martin gained 8%, and RTX, previously known as Raytheon, rallied 4%. The explosion in hostilities between Israel and Hamas tokenexus review: important information for you sent US defense stocks surging on Monday as the war looks to play out for a while and threatens to expand regionally. Indeed, according to Insider’s own research, stock valuations are looking increasingly stretched, raising the risk of a correction.

  • The answer depends on the investor’s personal situation, encompassing factors such as age and risk tolerance.
  • Firstly, most individuals find peace of mind and financial stability in having a clean balance sheet, as well as some financial uptick.
  • The rally was fueled by slower inflation and hype over artificial intelligence.
  • So far, the US has spent more than $40 billion on military aid for Ukraine.
  • Each earnings report next year could show escalating profits, outdoing the market’s favorable estimates.

Like Zoom, Teladoc Health (TDOC -0.16%) is benefiting from the shift toward cloud-based video communications. People can use the virtual healthcare leader’s platform to have video chat consultations with doctors, therapists, and other health experts using their computers and mobile devices. Telehealth services are allowing hospitals to provide more care to more people at a time when physical capacity at many medical facilities is stretched thin due to COVID-19.

Costco Wholesale Corporation (NASDAQ:COST)

The result beat analysts’ forecasts, which called for a profit of $3.95 a share, according to FactSet. JPMorgan shares rose 3.6% in late-morning trading on Wall Street. Fortunately, some of our best companies are helping us combat COVID-19. In turn, these businesses are set to not just survive, but thrive, during these difficult times and emerge even stronger from the crisis. Regeneron plans to produce in the neighborhood of 100,000 doses in January, and has set a target for production capacity of 2 million doses per year. It previously signed a $450 million deal with the U.S. government to supply enough doses to treat about 300,000 patients.

  • You can even that out by investing your money in the entire market – think the Russell 3000 – and letting the chips fall on specific companies where they may.
  • Thirty-nine analysts have PYPL among their buy-worthy coronavirus stocks, while just six say Hold and a lone pro says Sell.
  • Billy Duberstein has no position in any of the stocks mentioned.
  • However, Wall Street remains apprehensive, as many companies have continued to suffer from reductions in consumer spending.

Zoom should continue to add new users at a rapid clip, boosting its revenue and profits — and returns to shareholders — along the way. If you buy shares of the following stocks now, you’ll likely earn strong returns on your investment, while helping to support the companies that give us the best chance at containing the coronavirus pandemic. Hold diversified stock funds for higher returns and bond funds for income and stability (though bonds haven’t been paragons of stability lately), and stick with them. Stash the money you need to pay the bills in money-market funds, short-term savings accounts and Treasury bills. The company’s most recent results included a Street-beating $793 million in revenues (+12% year-over-year) and better-than-expected earnings of $1.31 per share. And numerous analysts continue to believe AKAM will be among the better coronavirus stocks to buy heading into 2021.

Abbott (ABT 0.75%) made $1.9 billion in the third quarter from sales of its COVID-19 testing products. The company expects to generate between $1 billion and $1.4 billion from its COVID-19 tests in the fourth quarter. It’s a pretty safe bet that sales total will increase as the omicron variant spreads over the coming months.

Make a sensible ‘me fund’

« We view shares as undervalued at 17.5 times our estimated 2021 EPS of $5.48, which is below the midpoint of its historical times range, » William Blair’s Jim Breen (Outperform) wrote in late October. « We believe Akamai is strategically well positioned in an industry with supportive underlying fundamentals. » « We olymp trade forex broker review believe that an Outperform rating is warranted given valuation upside and an unrivaled collection of high-profile and omnipresent core products and platforms. » Although the WHO later clarified its comments, the damage was already done. Cash quickly became persona non grata at many stores and restaurants.

Working with an adviser may come with potential downsides such as payment of fees (which will reduce returns). There are no guarantees that working with an adviser will yield positive returns. The existence of a fiduciary duty does not prevent the rise of potential conflicts of interest. For the foreseeable future, just about any degree of risk will be significantly magnified, particularly when it comes to buying individual equities.

For example, Boeing’s CEO Dave Calhoun has already told investors that composites will be a significant part of any new plane the company develops. That’s driven by the cost and durability advantages of using advanced composites over traditional materials such as aluminum. Hexcel claims its carbon fiber is five times stronger than aluminum and 30% lighter. That reduces lifecycle costs and makes airplanes more fuel efficient. In Costco’s Q (ending in August), revenue rose 9.5% year over year, beating analysts’ forecasts by more than $1 billion. The company has stayed resilient despite economic headwinds, making it an excellent stock for the long term.

These two exciting growth companies have cyclical (end market) and secular (technological adoption) growth drivers.

Akamai Technologies (AKAM, $102.71) is one of those tech companies that most people only know if they have a reason to. For instance, in June, CNBC reported that kitchen and bath remodeling projects were up 40% compared to last year, home extensions and additions improved by 52%, and fence installations and repairs jumped 166%. Lumber joined toilet paper and hand sanitizer as an early victim of coronavirus shortages. While it’s easy to find toilet paper and hand sanitizer now, lumber remains in short supply due to all those home renovation projects. Given that more than 90% of Alphabet’s 2019 revenues were generated by advertising (whether via Google or YouTube), any ad-spending cutbacks would certainly be felt.


Airbnb is one of many lodging stocks that might get a bounce over the coming years as people begin to travel again. Airbnb might be of particular interest as many of its hosts rent out their own homes on the platform, something they simply couldn’t do during the pandemic. Now that restrictions are easing, there’s likely to be much more commerce on the website, and the stock might trend upwards as a result.

Premium Investing Services

I won’t be surprised if Lilly achieves success with at least one of its coronavirus efforts. In the meantime, the company’s diabetes drug franchise continues chapter 20 numerical differentiation to rock along thanks primarily to strong sales for Jardiance and Trulicity. Lilly is also a top contender in the immunology market with Olumiant and Taltz.

Gilead Sciences (GILD 1.16%) is another powerful ally in the war against COVID-19. The biotechnology giant’s experiential drug remdesivir is regarded as a promising potential treatment for the disease. Remdesivir exhibited encouraging results in animal models for treating SARS and MERS, which are also caused by coronaviruses that are structurally similar to COVID-19. In turn, health officials believe Gilead’s drug could prove useful as a treatment for COVID-19.

The biotechnology company has developed a vaccine that clinical trials have shown to be 94% effective against COVID and as much as 100% effective at preventing severe forms of the disease. Governments have rushed to secure massive quantities of Moderna’s vaccine, which has brought much-needed cash into the drugmaker’s coffers. Moderna intends to use this cash to fund the development of new vaccines for other illnesses, which could fuel its already impressive growth in the coming years. Like all investing strategies, this will mean passing up on some opportunities in order to mitigate risk. You will not be able to time the market and flood all your money in at its low point.

In fact, in early May – when SHOP was trading in the $700 range (it’s now well over $1,000) – Shopify became Canada’s most valuable publicly traded company. Its chips power servers that need parallel processing for intensive processes including artificial intelligence, machine learning, autonomous automotive applications and data science. Akamai operates the world’s largest content delivery network (CDN). A CDN uses clusters of web servers that either host websites, or cache content, offering improved security and faster performance.